Alpha Teknova (TKNO)

Preface

Our focus on top-down thematic trends and basket-level exposure occasionally minimizes the impact of single-name equities, which is why we’ve made it a focus to seek out conversations with the management of companies directly benefitting from and/or driving these market themes in our “In Conversation” series. 

We recently had the opportunity to meet with Stephen Gunstream, CEO of Alpha Teknova (TKNO US) for a tour of their newly operational production facility and a wide-ranging discussion on the life sciences and bioprocessing industries. 

We discussed the exciting therapeutic innovations that are transforming medicine, the current state of demand in the bioprocessing industry, and the transformation the company has undergone over the last couple of years that position it to capitalize on the opportunity in front of them.

TKNO has been one of the top performers in our core model portfolio since it was added on July 23rd 2024 with a gain of +113%. Since we released our thematic primer on August 5th 2024, it is up 28% - contributing significantly to the basket’s overall gain of +9.94% since inception.